Evidence map›Paper›PMID 29508003›Full record

ReviewDer Internist2018

[Pharmacological treatment of rheumatoid arthritis and its comorbidities].

K Krüger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. [Treat to target-participation of the patient].Zeitschrift fur Rheumatologie · 2019
    Review
  4. [Cardiovascular comorbidities in rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

K KrügerRheumatologisches Praxiszentrum München, St.-Bonifatius-Str. 5, 81541, München, Deutschland. klaus.krueger@med.uni-muenchen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to therapeutic advances, rheumatoid arthritis (RA) today has developed into a satisfactorily treatable disease in most cases, with remission being the target of treatment. Early diagnosis with immediate treatment initiation following treat-to-target strategy is the key to a favorable long-term outcome. A guideline-directed treatment algorithm determines the use of conventional synthetic disease-modifying anti-rheumatic drugs (DMARD; e.g., methotrexate), biological DMARD, and targeted oral DMARD (Janus kinase inhibitors). Comorbidities-in particular cardiovascular and interstitial lung disease-affect 80% of RA patients and represent the leading causes for mortality. The choice of drug treatment is influenced by the presence of comorbidities.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidComorbidityDisability EvaluationDisease ProgressionGlucocorticoidsHumansQuality of LifeAntirheumatic AgentsGlucocorticoidsAntirheumatic drugs, disease-modifyingComorbidity, cardiovascularGlucocorticoidsLung disease, interstitialMolecular targeted therapy

Identifiers

PMID29508003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.